Revenue: As of FY2026 Q1, the actual value is USD 806.92 K.EPS: As of FY2026 Q1, the actual value is USD -0.2.EBIT: As of FY2026 Q1, the actual value is USD -547.87 K.Xenetic Biosciences, Inc. operates as a single operating segment, with its net loss serving as the measure of segment profit or loss .<h4>Revenue</h4><ul><li>Royalty revenue increased by $213,662, or 36.0%, from $593,261 for the three months ended March 31, 2025, to $806,923 for the three months ended March 31, 2026, primarily due to higher royalties from certain countries under the sublicense agreement with Takeda Pharmaceutical Co. Ltd. .</li></ul><h4>Operational Metrics</h4><ul><li>Research and development (R&amp;D) expenses decreased by $217,586, or 24.8%, from $879,029 in Q1 2025 to $661,443 in Q1 2026, mainly due to a decrease in pre-clinical and exploratory study costs, partially offset by increased manufacturing development efforts . Outside services and contract research organizations expenses were $658,229 in Q1 2026, down from $875,798 in Q1 2025 .</li><li>General and administrative expenses decreased by $9,044, or 1.4%, from $656,641 in Q1 2025 to $647,597 in Q1 2026, primarily due to lower personnel costs and share-based expense related to the interim Chief Executive Officer, largely offset by an increase in legal expenses .</li><li>Total operating costs and expenses decreased by $226,630, or 14.8%, from - $1,535,670 in Q1 2025 to - $1,309,040 in Q1 2026 .</li><li>Loss from operations decreased by $440,292, or 46.7%, from - $942,409 in Q1 2025 to - $502,117 in Q1 2026 .</li><li>Other (expense) income changed from $78 of income in Q1 2025 to - $21 of expense in Q1 2026, primarily due to unfavorable changes in foreign currency exchange rates .</li><li>Interest income, net, increased to $45,756 in Q1 2026 from $39,190 in Q1 2025, mainly due to higher average invested funds .</li><li>Net loss decreased by $446,759, or 49.5%, from - $903,141 in Q1 2025 to - $456,382 in Q1 2026 .</li><li>Accumulated deficit was - $200.3 million as of March 31, 2026, compared to - $199.9 million as of December 31, 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was - $536,377 for the three months ended March 31, 2026, compared to - $1,001,892 for the same period in 2025, primarily due to the net loss and a decrease in accounts payable, accrued expenses, and other liabilities .</li><li>There were no cash flows from investing activities for the three months ended March 31, 2026, and 2025 .</li><li>There were no cash flows from financing activities for the three months ended March 31, 2026, and 2025 .</li><li>Cash at end of period was $7,347,255 as of March 31, 2026, down from $7,883,632 at the beginning of the period .</li></ul><h4>Unique Metrics</h4><ul><li>Working capital was $6.6 million at March 31, 2026, a decrease of approximately $445,000 from $7.1 million at December 31, 2025, primarily due to the net loss .</li></ul><h4>Future Outlook and Strategy</h4><ul><li>Xenetic Biosciences, Inc. has initiated a formal strategic review process with financial and legal advisors to maximize shareholder value, considering alternatives such as a sale of all or part of the Company or its assets, or a business combination . The Company is committed to advancing its DNase technology, specifically focusing on its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors . While existing resources are believed to be adequate for at least twelve months, additional capital will be needed long-term for business initiatives, potentially through equity offerings, debt financings, or collaborations .</li></ul>

Xenetic Biosciences | 10-Q: FY2026 Q1 Revenue: USD 806.92 K